The specificity for prostate cancer detection on biopsy could be improved by fixing the sensitivity at 95%, with individual specificities of 15% for PSGR, 17% for PCA3, and 34% for the PSGR and PCA3 duplex panel [134]. The gene discussed is OR51E2; the disease is prostate cancer.